Recombinant Human Thrombopoietin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Recombinant Human Thrombopoietin
- DrugBank Accession Number
- DB16364
- Background
Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.1,2 This drug is used in the treatment of thrombocytopenia.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- rhTPO
- rHuTPO
- External IDs
- Recombinant Human Thrombopoietin
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
Recombinant human thrombopoietin has similar biological functions as endogenous thrombopoietin.2 It activates the thrombopoietin receptor MPL.1 This therapy has potential roles in hematopoietic stem and progenitor cell regeneration and is currently being investigated against relapsed immune thrombocytopenia, hematopoietic injury, and acute severe thrombocytopenia in sepsis.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Wang C, Zhang B, Wang S, Zhang J, Liu Y, Wang J, Fan Z, Lv Y, Zhang X, He L, Chen L, Xia H, Li Y, Pei X: Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation. Sci Rep. 2015 Sep 25;5:12993. doi: 10.1038/srep12993. [Article]
- Zhou Z, Feng T, Xie Y, Huang P, Xie H, Tian R, Qian B, Wang R: The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial). BMC Infect Dis. 2019 Sep 6;19(1):780. doi: 10.1186/s12879-019-4388-2. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Thrombocytopenia 1 4 Recruiting Treatment Chronic Liver Diseases (CLD) / Thrombocytopenia; Drugs 1 4 Recruiting Treatment Primary Immune Thrombocytopenia 1 4 Recruiting Treatment Thrombocytopenia 1 4 Unknown Status Treatment Allogeneic peripheral haematopoietic stem cell transplant / Delayed Platelet Engraftment / Myeloablative 1 3 Completed Prevention Sarcomas 1 3 Completed Treatment Hematologic Diseases / Thrombocytopenia 1 3 Completed Treatment Idiopathic Thrombocytopenic Purpura / Purpura 3 3 Completed Treatment Immune Thrombocytopenia 1 3 Completed Treatment Immune Thrombocytopenia / Pregnant State 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution 15000 iu/1ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 17, 2020 22:51 / Updated on May 05, 2021 20:32